![Jakob Dupont](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jakob Dupont
Directeur/Membre du Conseil chez
BOLT BIOTHERAPEUTICS, INC.
Fortune : 72 385 $ au 31/05/2026
Profil
Jakob Dupont is currently an Independent Non-Executive Director at Imugene Ltd. since 2022, a Director at Avenzo Therapeutics, Inc. since 2024, an Independent Director at Pyxis Oncology, Inc. since 2023, a Director at Bolt Biotherapeutics, Inc. since 2024, an Executive Partner at Sofinnova Investments, Inc. since 2023, and an Advisor at Ambrx, Inc. since 2021.
Former roles include Global Director-Medical at Genentech, Inc. from 2006 to 2011, Director at Apexigen America, Inc. from 2020 to 2023, Independent Director at Apexigen, Inc. from 2020 to 2023, VP & Global Head-Gynecologic Cancer Development at Genentech, Inc. from 2017 to 2018, Faculty Member at Memorial Sloan Kettering Cancer Center, Chief Medical Officer & Senior Vice President at Mereo BioPharma 5, Inc. from 2012 to 2016, EVP, Global Head-Research & Development at Atara Biotherapeutics, Inc. from 2020 to 2023, and Chief Medical Officer at Gossamer Bio, Inc. from 2018 to 2020.
Education includes graduate degree from New York University in 1991, undergraduate degree from Vassar College in 1987, and doctorate from Weill Cornell Medical College in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC. 0,06% | 20/04/2026 | 38 741 ( 0,06% ) | 69 734 $ | 31/05/2026 |
IMUGENE LTD 0,01% | 17/12/2025 | 32 038 ( 0,01% ) | 2 651 $ | 31/05/2026 |
| 10/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Jakob Dupont
| Sociétés | Poste | Début |
|---|---|---|
| IMUGENE LIMITED | Directeur/Membre du Conseil | 07/09/2022 |
| AMBRX INC | Consultant / Advisor | 01/03/2021 |
| PYXIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 23/08/2023 |
| BOLT BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/09/2024 |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Private Equity Investor | 01/05/2023 |
Avenzo Therapeutics, Inc.
 Avenzo Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development for oncology therapies used in treating of cancer | Directeur/Membre du Conseil | 01/03/2024 |
Anciens postes connus de Jakob Dupont
| Sociétés | Poste | Fin |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/12/2023 |
| APEXIGEN, INC. | Directeur/Membre du Conseil | 23/08/2023 |
Apexigen America, Inc.
 Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology | Directeur/Membre du Conseil | 01/08/2023 |
| ░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jakob Dupont
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Mereo BioPharma 5, Inc.
 Mereo BioPharma 5, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-cancer stem cell therapeutics | Health Technology |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Finance |
Imugene Ltd.
 Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vassar College
 Vassar College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx, Inc.
 Ambrx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates cancer hospital | Health Services |
Weill Cornell Medical College
 Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology | Health Technology |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Bolt Biotherapeutics, Inc.
 Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Gossamer Bio, Inc.
 Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
Apexigen, Inc.
 Apexigen, Inc. BiotechnologyHealth Technology Develops antibody therapeutics for the treatment of cancer | Health Technology |
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development for oncology therapies used in treating of cancer | Health Technology |
